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Abstract
Background: Treatment is the principle way to control and eliminate piroplasmosis. The search for new
chemotherapy against Babesia and Theileria has become increasingly urgent due to parasite resistance to current
drugs. Ivermectin (IVM) was the world’s first endectocide, capable of killing a wide variety of parasites and vectors,
both inside and outside the body. It is currently authorized to treat onchocerciasis, lymphatic filariasis,
strongyloidiasis, and scabies. The current study documented the efficacy of IVM on the growth of Babesia and
Theileria in vitro and in vivo.
Methods: The fluorescence-based assay was used for evaluating the inhibitory effect of IVM on four Babesia
species, including B. bovis, B. bigemina, B. divergens, B. caballi, and Theileria equi, the combination with diminazene
aceturate (DA), clofazimine (CF), and atovaquone (AQ) on in vitro cultures, and on the multiplication of a B. microti-
infected mouse model. The cytotoxicity of compounds was tested on Madin–Darby bovine kidney (MDBK), mouse
embryonic fibroblast (NIH/3 T3), and human foreskin fibroblast (HFF) cell lines.
Results: The half-maximal inhibitory concentration (IC50) values determined for IVM against B. bovis, B. bigemina, B.
divergens, B. caballi, and T. equi were 53.3 ± 4.8, 98.6 ± 5.7, 30.1 ± 2.2, 43.7 ± 3.7, and 90.1 ± 8.1 μM, respectively. Toxicity
assays on MDBK, NIH/3 T3, and HFF cell lines showed that IVM affected the viability of cells with a half-maximal
effective concentration (EC50) of 138.9 ± 4.9, 283.8 ± 3.6, and 287.5 ± 7.6 μM, respectively. In the in vivo experiment, IVM,
when administered intraperitoneally at 4 mg/kg, significantly (p < 0.05) inhibited the growth of B. microti in mice by
63%. Furthermore, combination therapies of IVM–DA, IVM–AQ, and IVM–CF at a half dose reduced the peak
parasitemia of B. microti by 83.7%, 76.5%, and 74.4%, respectively. Moreover, this study confirmed the absence of B.
microti DNA in groups treated with combination chemotherapy of IVM + DA and IVM + AQ 49 days after infection.
Conclusions: These findings suggest that IVM has the potential to be an alternative remedy for treating piroplasmosis.
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Background
Babesiosis is a malaria-like parasitic disease caused by
Babesia, a genus of Apicomplexa [1]. Babesia bovis, B.
bigemina, and B. divergens infect cattle, causing bovine
babesiosis. In Europe, bovine babesiosis, known as red
water fever, is mainly caused by B. divergens and is con-
sidered the most important tick-transmitted disease in
cattle [2], while B. caballi and Theileria equi infect
horses causing equine piroplasmosis [3]. Human
babesiosis is uncommon; however, it is important as an
emerging disease in the Northeastern and Midwestern
United States and parts of Europe, and sporadic
throughout the rest of the world [4]. The spectrum of
human babesiosis is broad, ranging from an apparently
silent infection to a fulminant, malaria-like disease
resulting occasionally in death [5].
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Treatment of babesiosis and theileriosis in animals de-
pends on two common drugs, namely diminazene acetu-
rate (DA) and imidocarb dipropionate, while human
babesiosis has been managed with a combination of atova-
quone (AQ) and azithromycin and a combination of clin-
damycin and quinine [6]. Recently, González et al. showed
the failure, ineffectiveness, adverse reaction, and relapsing
babesiosis of clindamycin and quinine combination treat-
ment in splenectomized patients infected by B. divergens
or B. microti [7], while Hatcher et al. showed that patients
affected by severe babesiosis had adverse reactions to
quinine treatment and persistently high parasitemia more
than 10 days after treatment with a combination of AQ
and azithromycin [8]. In addition, Babesia gibsoni has
been shown to be resistant to AQ [9]. Therefore, research
to find new drugs and drug targets is the fundamental ap-
proach for addressing current limitations.
Ivermectin (IVM) is a macrocyclic lactone derived
from avermectin, which is produced by an actinomycete,
Streptomyces avermitilis [10]. IVM is a safe drug active
against a wide range of internal and external parasites,
and it is used widely in both veterinary and human
medicine [11, 12]. In human medicine, IVM is used to
treat onchocerciasis (river blindness). IVM is effective
against many worm infestations (such as strongyloidiasis,
ascariasis, trichuriasis, filariasis, and enterobiasis) and
some epidermal parasitic skin diseases, including scabies
[13]. Originally thought to have antibacterial or antiviral
properties, IVM has recently been reported to kill Myco-
bacterium tuberculosis, including multidrug-resistant
strains [14]. IVM induces chloride-dependent membrane
hyperpolarization and cell death in leukemia cells,
prompting suggestions that it could be rapidly put into
clinical trials for leukemia. IVM was shown to be a
highly potent inhibitor of yellow fever virus replication
and the replication of several other flaviviruses, notably
dengue, Japanese encephalitis, and tick-borne encephal-
itis [14]. Recently, the endectocide IVM has arisen as a
promising new tool to be added to malaria control pro-
grams [12]. Moreover, new possible uses are continuing
to emerge, heralding potential breakthroughs in tackling
various neglected tropical diseases—and beyond. Re-
search has shown that, for human African trypanosomia-
sis (sleeping sickness), deworming cattle with single
doses of IVM decrease the survival and fecundity of
disease-transmitting tsetse flies feeding on cattle by up
to 94% [15]. IVM is also efficacious in curing cutaneous
leishmaniasis, killing Leishmania parasites in vitro and
via subcutaneous inoculation [16].
In veterinary medicine, IVM is used against many intes-
tinal worms, most mites, and some lice. It is sometimes
administered in combination with other medications to
treat a broad spectrum of animal parasites [10]. In
addition, IVM can be given by mouth, topically, or via
injection. As a drug targeting nematode and arthropod
parasites, IVM has not been reported to directly interact
with any mammalian proteins with high selectivity [17]. In
this study, we evaluated the effects of IVM against the
growth of B. bigemina, B. bovis, B. divergens, B. caballi,
and T. equi in vitro as well as the chemotherapeutic po-
tential of IVM on B. microti in vivo.
Results
The growth inhibitory effect of IVM against Babesia and
Theileria
Growth inhibitory assays were conducted on five species:
B. bovis, B. bigemina, B. divergens, B. caballi, and T.
equi. IVM inhibited the multiplication and growth of all
species tested in a dose-dependent manner (Figs. 1 and
2). The half-maximal inhibitory concentration (IC50)
values of IVM on B. bovis, B. bigemina, B. divergens, B.
caballi, and T. equi were 53.3 ± 4.8, 98.6 ± 5.7, 30.1 ± 2.2,
43.7 ± 3.7, and 90.1 ± 8.1 μM, respectively (Table 1). In
this study, diminazene aceturate (DA) showed IC50
values at 0.35, 0.68, 0.43, 0.022, and 0.71 μM against B.
bovis, B. bigemina, B. divergens, B. caballi, and T. equi,
respectively. Atovaquone (AQ) showed IC50 values at
0.039, 0.701, 0.038, 0.102, and 0.095 μM against B. bovis,
B. bigemina, B. divergens, B. caballi, and T. equi, re-
spectively. Clofazimine (CF) showed IC50 values at 8.24,
5.73, 13.85, 7.95, and 2.88 μM against B. bovis, B. bige-
mina, B. divergens, B. caballi, and T. equi, respectively
(Additional file 3: Table S3). The effectiveness of IVM
was not influenced by the diluent since there was no sig-
nificant difference in the inhibition between wells con-
taining DMSO and untreated wells. The precultivation
of RBCs with IVM was conducted to determine its
direct effect on host RBCs. Bovine and equine RBCs
were incubated with IVM at 10, 100, and 200 μM for
3 and 6 h to be used for the parasite subculture. The
multiplication of all parasites did not significantly dif-
fer between IVM-treated RBCs and normal RBCs for
either species (data not shown).
Toxicity of IVM, DA, AQ, and CF on MDBK, NIH/3 T3, and
HFF cell lines
IVM showed an inhibitory effect on the in vitro culture
of Babesia and Theileria parasites. Therefore, the effect
of IVM on host cells was evaluated using Madin–Darby
bovine kidney (MDBK), NIH/3 T3, and human foreskin
fibroblast (HFF) cell lines to see the cytotoxicity of the
IVM compound (Table 1). The half-maximal effective
concentration (EC50) values of IVM on MDBK, NIH/3
T3, and HFF cell lines were 138.9 ± 4.9, 283.8 ± 3.6, and
287.5 ± 7.6 μM, respectively. The selectivity indexes are
defined as the ratio of cell line EC50 to the parasite IC50.
The highest selectivity index was achieved on B. diver-
gens; as in the case of the MDBK cell line, it was found
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to be 4.6 times higher than the IC50; while in case of the
NIH/3 T3 cell line, it was found to be 9.4 times higher
than the IC50; and in case of the HFF cell line, it was
found to be 9.6 times higher than the IC50 (Table 1). In
a separate assay, DA and AQ at concentrations of
100 μM did not show any inhibition of MDBK, NIH/3
T3, and HFF cell viability, while CF showed inhibition
only on MDBK with an EC50 value at 34 ± 3.4 μM (Add-
itional file 3: Table S3). The highest selectivity index
of DA was achieved on B. caballi, while for AQ and
CF the highest selectivity index was achieved against
B. divergens and T. equi, respectively (Additional
file 3: Table S3).
The viability of parasites treated with IVM
A viability assay was performed to determine whether
the concentrations of IVM could completely clear para-
sites after 4 days of successive treatment, followed by
withdrawal of the drug pressure. B. bovis, B. bigemina,
B. divergens, and B. caballi treated with IVM could not
regrow at the concentration of 4 × IC50, while T. equi
could regrow at the concentration of 4 × IC50 (Table 2).
Fig. 1 The dose-response curves of ivermectin against bovine Babesia parasites in vitro. The curve shows the correlation between relative
fluorescence units (RFUs) and the log concentrations of IVM (μM) in B. bovis, B. bigemina, and B. divergens treated with various concentrations of
IVM. The result was determined by fluorescence assay after 96 h of incubation. The values obtained from three separate trials were used to
determine the IC50s using nonlinear regression (curve fitting analysis) in GraphPadPrism software
Fig. 2 The dose-response curves of ivermectin against equine piroplasm parasites in vitro. The curve shows the correlation between relative
fluorescence units (RFUs) and the log concentrations of IVM (μM) in B. caballi and T. equi treated with various concentrations of IVM. The result
was determined by fluorescence assay after 96 h of incubation. The values obtained from three separate trials were used to determine the IC50s
using nonlinear regression (curve fitting analysis) in GraphPadPrism software
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The effects of the combination of IVM with DA, AQ, and
CF in vitro
The drug combination assay was performed to examine
whether the combined treatments are synergism (give a
greater effect), additive (similar effect), or antagonism (re-
duce or block the effect). Five selected concentrations of
IVM, as recommended in the Chou–Talalay method [18],
were combined with DA, AQ, and CF at a constant ratio of
(1:1). The percentage of inhibition of the single drug and
each combination was analyzed using CompuSyn software
to generate the combination index (CI) value at IC50, IC75,
IC90, and IC95 (Additional file 2: Table S2). The drug com-
bination effect was considered synergetic if the value was
less than 0.90, additive if the value was at a range of 0.90–
1.10, and antagonistic if the value was more than 1.10. The
effects of combination treatment of IVM-DA, IVM-AQ,
and IVM-CF against B. bovis, B. bigemina, B. divergens, B.
caballi, and T. equi are shown in Table 3. The combination
treatments of IVM-DA showed synergistic effects against B.
bigemina, B. divergens, and B. caballi, and an additive effect
against B. bovis and T. equi. The combination treatments of
IVM-AQ showed a synergistic effect against B. bigemina
but an additive effect against B. bovis, B. divergens, B.
caballi, and T. equi. Combination treatments of IVM-CF
showed additive effects against B. bovis, B. bigemina, B.
divergens, B. caballi, and T. equi, while none of the combi-
nations showed an antagonistic effect.
The chemotherapeutic effect of IVM against B. microti
For further evaluation of IVM efficacy as compared with
other drugs, the chemotherapeutic effect of IVM was ex-
amined in mice infected with B. microti (Fig. 3). In the
DDW control group, the multiplication of B. microti in-
creased significantly, reaching the highest parasitemia at
58.2% on day 8 post-infection (p.i). In all treated groups,
the level of parasitemia was cleared at a significantly lower
percentage of parasitemia than the control group
(p < 0.05) from day’s 6 to 12 p.i. In mono-chemotherapy-
treated mice, the peak parasitemia level reached 21.5%,
3.9%, and 4.3% on day 8 and 4.9% on day 7 in 4 mg/kg
IVM, 25 mg/kg DA, 20 mg/kg AQ, and 20 mg/kg CF, re-
spectively (Fig. 3). The parasitemia was undetectable in
mice treated with 25 mg/kg DA, 20 mg/kg AQ, and
20 mg/kg CF via microscopy starting on day 13, 15, and
16 p.i., respectively. The parasitemia was undetectable by
microscopy examination in mice treated with 4 mg/kg of
IVM on day 30 p.i., while in the combination chemother-
apy-treated groups, peak parasitemia levels reached 9.5%,
15%, and 14% in 2 mg/kg IVM–12.5 mg/kg DA on day 8,
2 mg/kg IVM–10 mg/kg CF on day 7, and 2 mg/kg IVM–
10 mg/kg AQ on day 8, respectively (Fig. 4). Parasitemia
was undetectable by microscopic examination in mice on
days 13, 22, and 18 p.i. with 2 mg/kg IVM–12.5 mg/kg DA,
2 mg/kg IVM–10 mg/kg CF, and 2 mg/kg IVM–10 mg/kg
AQ, respectively. Infection with B. microti reduced the
Table 1 IC50 and selectivity index of IVM
Compound Babesia
and
Theileria
IC50
(μM)a
EC50 (μM)
b Selective indicesc
MDBK NIH/3 T3 HFF MDBK NIH/3 T3 HFF
IVM B. bovis 53.3 ± 4.8 138.9 ± 4.9 283.8 ± 3.6 287.5 ± 7.6 2.6 5.3 5.4
B. bigemina 98.6 ± 5.7 138.9 ± 4.9 283.8 ± 3.6 287.5 ± 7.6 1.4 2.9 2.9
B. divergens 30.1 ± 2.2 138.9 ± 4.9 283.8 ± 3.6 287.5 ± 7.6 4.6 9.4 9.6
B. caballi 43.7 ± 3.7 138.9 ± 4.9 283.8 ± 3.6 287.5 ± 7.6 3.2 6.5 6.6
T. equi 90.1 ± 8.1 138.9 ± 4.9 283.8 ± 3.6 287.5 ± 7.6 1.5 3.1 3.2
aHalf-maximal inhibition concentration of ivermectin on the in vitro culture of parasites. The value was determined from the dose-response curve using nonlinear
regression (curve fit analysis). The values are the means of triplicate experiments
bHalf-maximal effective concentration of ivermectin on cell lines. The values were determined from the dose-response curve using nonlinear regression (curve fit
analysis). The values are the means of triplicate experiments
cRatio of the EC50 of cell lines to the IC50 of each species. High numbers are favorable
IVM ivermectin, MDBK Madin–Darby bovine kidney, NIH/3 T3 Mouse embryonic fibroblast, HFF Human foreskin fibroblast
Table 2 The viability of Babesia and Theileria parasites treated with IVM
Drugs Conc. of
compounds
Parasites
B. bovis B. bigemina B. divergens B. caballi T. equi
IVM 0.25 × IC50 + + + + +
0.5 × IC50 + + + + +
1 × IC50 + + + + +
2 × IC50 + + + + +
4 × IC50 – – – – +
Untreated control + + + + +
The positive (+) shows the regrowth of parasites, and the negative (−) shows the total clearance of parasites on day 8 after withdrawing the drug pressure
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hematocrit (HCT) count, hemoglobin (HGB) percentage,
and red blood cell (RBC) count in mouse blood, as ob-
served in the DDW control group on days 8, 12, 16, and 20
p.i. Significantly higher differences (p < 0.05) in HCT count,
HGB percentage, and RBC count were observed between
the DDW control group and all drug-treated groups on days
8, 12, 16, and 20 (Fig. 5a–c). Furthermore, parasite DNA was
not detected in 25 mg/kg DA-IP, 2 mg/kg IVM–12.5 mg/kg
DA, or 2 mg/kg IVM–10 mg/kg AQ on day 49. Meanwhile,
in all other groups—20 mg/kg AQ–oral, 20 mg/kg CF–oral,
4 mg/kg IVM–IP, and 2 mg/kg IVM–10 mg/kg CF—parasite
DNA was detected until day 49 (Fig. 6).
Discussion
Although several reports documented the efficacy of
IVM in the tick control programs to prevent the tick
transmission of several Babesia and Theileria species to
cattle and dogs [19, 20], this is the first study to evaluate
the efficacy of IVM as an antiparasitic agent against Ba-
besia and Theileria parasites in vitro and in vivo. In the
current study, IVM inhibited the growth of B. bovis, B.
bigemina, B. divergens, B. caballi, and T. equi in vitro.
However, IVM showed slightly high IC50 values; they are
still lower than those of N-acetyl L-cysteine [21], allicin
[22], and clodinafop-propargyl against bovine Babesia
Table 3 The effect of ivermectin with diminazene aceturate, atovaquone, and clofazimine against Babesia and Theileria parasites in
vitro
Drug
combinations
Parasites
B. bovis B. bigemina B. divergens B. caballi T. equi
IVM + DA CI values 1.11051 0.40539 0.01779 0.14328 1.10124
Degree of association Additive Synergistic Synergistic Synergistic Additive
IVM + AQ CI values 1.04737 0.82283 1.04901 1.07398 1.05367
Degree of association Additive Synergistic Additive Additive Additive
IVM + CF CI values 0.92317 1.01390 1.01372 1.10847 0.99644
Degree of association Additive Additive Additive Additive Additive
CI combination index, AQ atovaquone, CF clofazimine, DA diminazene aceturate
Fig. 3 The growth inhibition of IVM on B. microti in vivo. Graph showing the inhibitory effects of DA-IP, AQ-oral, CF-oral, IVM-IP treatment as
compared to the untreated group. The values plotted indicate the mean ± standard deviation for two separate experiments. Asterisks (*) indicate
statistical significance (p < 0.05) based on one-way ANOVA Tukey’s test using GraphPad Prism version 5.0 for Windows (GraphPad Software Inc.,
San Diego, CA, USA). The arrow indicates five consecutive days of treatment. Parasitemia was calculated by counting infected RBCs among 2000
RBCs using Giemsa-stained thin blood smears
Batiha et al. Tropical Medicine and Health           (2019) 47:42 Page 5 of 12
and equine Babesia/Theileria parasites [23], and metro-
nidazole and clindamycin phosphate against B. gibsoni
[24]. Interestingly, several reports documented the ef-
fectiveness of IVM on Plasmodium which is one of the
apicomplexan parasites closely related to Babesia and
Theileria [25], and on Leishmania, and Trypanosoma
parasites [15, 16]. This emphasizes that IVM is effective
against many protozoan parasites.
Cytotoxicity studies showed that IVM was more likely
to affect Babesia and Theileria than the host cells. This
finding was consistent with that of Dou et al., who
showed that IVM decreased the viability of breast cancer
cell lines in a dose-dependent manner without cytotoxic
activities on host cells [26].
Strikingly, the viability assay showed that IVM was
more effective against Babesia than against Theileria
parasites. B. bovis, B. divergens, B. bigemina, and B.
caballi could not regrow with 4 × IC50 treatments of
IVM, while T. equi could regrow at 4 × IC50 of IVM.
This indicates that T. equi has better coping mechanisms
to IVM treatment than Babesia parasites do. This find-
ing is compatible with Reece et al., who reported that
different malaria parasites species have used different
coping mechanisms by changing in their investment in
gametocytes during infections depending on their envir-
onment [27]. However, these patterns seem confusing;
they can explain how parasites can respond to changes
happened during infection. Therefore, T. equi might act
by a different mechanism of action than that for Babesia
species for coping the stress caused by IVM treatment.
That may be one of the explanations of how can T. equi
can be recovered again after the withdrawal of the drug
pressure on the fourth day. However, we are unable to
reach a definitive conclusion, since this study did not
confirm the mode of action of IVM against Babesia and
Theileria parasites. This finding is consistent with that
of Tayebwa et al., who explained that T. equi might be
affected through a different pathway than that for Babe-
sia species [28].
Interestingly, combination chemotherapy has been rec-
ommended against drug-resistant protozoal and bacter-
ial pathogens. Since, IVM is a well-known antiparasitic
drug with a broad spectrum of activity, high efficacy,
and it is used widely in the veterinary and human medi-
cine [11, 12]. Additionally, the inhibition and cytotox-
icity assays in the current study revealed that IVM
showed higher IC50 values and lower selective index
than currently available antibabesial drugs (DA, AQ, and
CF). Therefore, the combination study aimed to enhance
the potency of IVM while reducing the dose that led to
reduced toxicity, subsequently reducing their toxic side
effects. The in vitro combination treatment of IVM with
Fig. 4 The growth inhibition of IVM combinations on B. microti in vivo. The graph shows the inhibitory effects of DA, AQ, and CF combined with
IVM treatments as compared with the untreated group. The values plotted indicate the mean ± standard deviation for two separate experiments.
The asterisks (*) indicate statistical significance (p < 0.05) based on one-way ANOVA Tukey’s test using GraphPad Prism version 5.0 for Windows
(GraphPad Software Inc., San Diego, CA, USA). The arrow indicates five consecutive days of treatment. Parasitemia was calculated by counting
infected RBCs among 2000 RBCs using Giemsa-stained thin blood smears
Batiha et al. Tropical Medicine and Health           (2019) 47:42 Page 6 of 12
DA, AQ, or CF revealed synergistic and additive effects
against Babesia and Theileria parasites. Whereas, in the
combination chemotherapy, drugs that share the same
mode of action tend to yield a synergistic effect, which
can be defined as the greater effect of two drugs in the
combination than the sum of each drug when acting
separately, or an additive effect, in which two drugs in
the combination produce an effect equal to the sum of
each drug when acting separately. Therefore, there is a
need for further studies to reveal the exact mechanism
of action of IVM against Babesia and Theileria and then,
clarify the reason behind this synergetic and additive ef-
fect of the combined treatment with DA, AQ, and CF
and choose the best combination to be used in the field.
The promising efficacy of IVM in vitro prompted us to
evaluate its performance in vivo. IVM administered
Fig. 5 Changes in the hematocrit count (a), hemoglobin percentage (b), and red blood cell count (c) in IVM-treated mice in vivo. The graphs
show changes in the hematocrit count (a), hemoglobin percentage (b), and red blood cell count (c) of mice treated as compared with untreated
mice. The different groups used were DA-IP, AQ-oral, CF-oral, IVM-IP, IVM-DA, IVM-AQ, IVM-CF, and untreated mice. The values plotted are the
mean ± standard deviation for two separate trials. Each group contained five mice. Asterisks (*) indicate statistical significance (p < 0.05) based on
one-way ANOVA Tukey’s test using GraphPad Prism version 5.0 for Windows (GraphPad Software Inc., San Diego, CA, USA). The arrow indicates
five consecutive days of treatment
Fig. 6 Molecular detection of parasite DNA in the treated groups. The image shows the molecular detection of parasites in the blood of treated
groups on day 49. M is for the marker, NC is for the untreated-uninfected group that was used as a negative control, PC is for the untreated-
infected group which used as the positive control, and C is for B. microti DNA control. The arrow shows the expected band length of 154 bp for
positive cases of B. microti. The double bands observed with some of the positive controls represent amplicons of the first and second PCR. While
a single band was observed in other groups due to the lower parasite DNA concentration
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intraperitoneally resulted in an inhibitory effect in vivo
but at lower rates than those with DA, AQ, and CF.
IVM–DA, IVM–AQ, and IVM–CF combinations were
evaluated in mice to determine whether combination
treatment would reduce the dose needed of the single
drugs without altering their therapeutic efficacy against
B. microti infection. Interestingly, our results are com-
patible with Mendes et al., who revealed that oral ad-
ministration of IVM at a concentration of 10 mg/kg
resulted in 80% inhibition of Plasmodium berghei in vivo
[29]. Additionally, Taman et al. documented that oral ad-
ministration of IVM at a concentration of 25 mg/kg re-
sulted in a significant reduction in Schistosoma mansoni
female worms. While, administration of the same dose
for two consecutive days revealed reduction of 45.4%,
27.6%, and 28.8% in female, male worms, and total
worm burdens, respectively when compared to infected
control groups receiving the vehicle only. Additionally,
IVM showed higher chemotherapeutic effect than a high
dose of praziquantel (six times higher dose than IVM),
which is the reference drug used for the treatment of
schistosomiasis [30]. Combination treatment of IVM–
DA, IVM–AQ, and IVM–CF at half doses improved the
efficacy of IVM at higher rates than those of monother-
apy. The potentiation of IVM that was achieved in in
vivo combination therapy confirmed the result that was
observed in vitro, which draws attention to IVM as a
good combinative drug. This finding is consistent with
Canton et al., who reported ivermectin (IVM) and rico-
bendazole (RBZ) combination obtained significantly
higher efficacy against IVM-resistant Haemonchus spp.
than IVM and RBZ alone which have been proposed as
a valid strategy to achieve effective nematode control in
the presence of drug resistance [31].
In order to confirm the ability of IVM to eliminate B.
microti, a PCR assay was performed on samples col-
lected on day 49 p.i. Interestingly, this study confirmed
the absence of B. microti DNA in groups treated with
combination chemotherapy of IVM–DA and IVM–AQ.
These results confirmed the importance of combination
chemotherapy in the effective control of piroplasmosis.
This finding further compels the need for combination
therapy to achieve optimal efficacy and prevent relapse
of infection or the development of a carrier state [32,
33]. Complimentarily, and consistent with a previous
study (Udensi and Fagbenro-Beyioku), IVM did not
show toxic side effects in mice [15]. Taken together,
the findings advocate that IVM is a potential drug
against human babesiosis as well as bovine and
equine piroplasmosis. Even though IVM showed
slightly low selective index, its combination with DA,
AQ, and CF at lower concentrations than the single
drugs could improve its effect and subsequently re-
duce its toxicity [32, 33].
Conclusion
IVM showed efficacies on Babesia and Theileria consist-
ent with efficacies reported on P. falciparum, Leish-
mania, and Trypanosoma. IVM effectiveness in vivo was
comparable to that showed by DA and showed no toxic
signs in mice. Therefore, IVM could be used as a che-
motherapeutic drug for piroplasmosis. However, further
studies are required to detect the exact mechanism of
action of IVM on Babesia and Theileria parasites.
Methods
Cultivation conditions
Parasites and mice
The United States Department of Agriculture (USDA)
strain of T. equi and B. caballi, the German bovine
strain of B. divergens [32], the Texas strain of B. bovis,
and the Argentina strain of B. bigemina were used for
the in vitro studies [28]; for the in vivo studies, B.
microti (Munich strain) was used [28, 34]. Eight-week-
old female BALB/c mice (CLEA Japan, Inc., Tokyo,
Japan) were housed in a pathogen-free environment with
controlled temperature (22 °C), humidity, and a 12 h
light/dark cycle, and used for cultivation of B. microti
for in vivo studies.
Chemicals and reagents
Ivermectin (IVM), diminazene aceturate (DA), atova-
quone (AQ), and clofazimine (CF) (Sigma-Aldrich,
Japan) were prepared in dimethyl sulfoxide (DMSO) in
stock solutions of 10 mM and stored at − 30 °C. A lysis
buffer containing Tris-HCl (130 mM at pH 7.5), EDTA
(10 mM), saponin (0.016% w/v), and Triton X–100 (1.6%
v/v) was prepared, filtered through 0.22 μm of polyether
sulfone, and stored at 4 °C to be mixed with 10,000×
SYBR Green I (SGI) nucleic acid stain (Lonza, USA)
0.2 μL/mL before measuring the fluorescence.
In vitro cultivation of parasites
Purified equine or bovine red blood cells (RBCs) were
used to maintain B. caballi, T. equi, B. bovis, B. bige-
mina, and B. divergens. A microaerophilic stationary-
phase culture system at 37 °C, 5% CO2, 5% O2, and 90%
N2 was used for the parasite cultivation as previously de-
scribed [32]. For B. bigemina and B. bovis culture,
medium 199 (M199; Sigma-Aldrich, Tokyo, Japan), sup-
plemented with 40% bovine serum, was used for cultiva-
tion, while medium RPMI 1640 (Sigma-Aldrich, Tokyo,
Japan) supplemented with 40% bovine serum was used
to culture B. divergens. GIT (Sigma-Aldrich, Tokyo,
Japan) supplemented with 40% equine serum was used
to maintain B. caballi culture, while M199 supplemented
with 40% equine serum and 13.6 μg/mL of hypoxanthine
was used for T. equi cultivation. Further, 60 μg/mL of
streptomycin and 0.15 μg/mL of amphotericin B were
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added to all of the culture media to prevent bacterial
and fungal contamination. In vitro cultures of all five
parasites were subcultured every 4 or 5 days to maintain
good parasite growth.
Cell cultures
Human foreskin fibroblast (HFF), Madin–Darby bovine
kidney (MDBK) cell lines, and mouse embryonic fibro-
blasts (NIH/3 T3) were maintained in 75 cm2 culture
flasks and incubated continuously at 37 °C in a humidified
incubator with 5% CO2. Minimum Essential Medium
Eagle (MEM; Gibco, Life Technologies, Grand Island, NY,
USA) was used for MDBK cell cultivation, while Dulbec-
co’s modified Eagle’s medium (DMEM; Gibco, Life Tech-
nologies, Grand Island, NY, USA) was used for NIH/3 T3
and HFF cell cultivation. Each medium was supplemented
with 10% fetal bovine serum, 50 μg/mL penicillin/strepto-
mycin (Gibco, Life Technologies, Grand Island, NY, USA),
and an additional 2 mM glutamine. The medium was
changed every 3 to 4 days and incubated until approxi-
mately 80% confluent. The cells were stained with 4,6-dia-
midino-2-phenylindole dihydrochloride (DAPI; Sigma-
Aldrich, St. Louis, MO, USA) to check mycoplasma-free
contamination. After that, the cells were washed two
times with Dulbecco’s phosphate-buffered saline (DPBS),
and TrypLE Express (Gibco, Life Technologies, Grand Is-
land, NY, USA) was used to allow cell detachment. Subse-
quently, viable cells were counted using a Neubauer
improved C-Chip (NanoEn Tek Inc., Seoul, Korea) after
staining with 0.4% Trypan blue solution.
Cytotoxicity assay of IVM on HFF, MDBK, and NIH/3 T3
cell lines
The drug-exposure viability assay was performed in ac-
cordance with the protocol described previously [32].
Briefly, 100 μL of cells at a density of 5 × 104 cells/mL
was seeded per well and allowed to attach to a 96-well
plate for 24 h at 37 °C in a humidified incubator with
5% CO2. For IVM, 10 μL of twofold dilutions was added
to each well to a final concentration of 12.5 μM to
500 μM in triplicate, while for DA, AQ, and CF, 10 μL
of twofold dilutions was added to each well, to a final
concentration of 100 μM in triplicate. Wells with only a
culture medium were used as blanks, while wells con-
taining cells and a medium with 0.4% DMSO were used
as a positive control. Subsequently, the plate was incu-
bated for another 24 h. Ten microliters of Cell Counting
Kit-8 (CCK-8) was added, and the plate was further in-
cubated for 3 h; the absorbance was then measured at
450 nm using a microplate reader.
The effects of IVM in host erythrocytes in vitro
The effects of IVM on bovine and equine RBCs were mea-
sured in accordance with the protocol previously
described [28]. Briefly, bovine and equine RBCs were in-
cubated in the presence of 10, 100, and 200 μM of IVM
for 3 and 6 h at 37 °C. Afterward, the erythrocytes were
washed thrice with drug-free media and used for the culti-
vation of B. bovis, B. bigemina, B. divergens, B. caballi,
and T. equi. The untreated RBCs were used as a control.
The effect was monitored using the fluorescence assay.
Growth inhibitory effects in vitro
A fluorescent assay was used to determine the half-
maximal inhibitory concentration (IC50) for IVM, DA,
AQ, and CF as previously described [28, 34]. Briefly,
IVM and CF in quantities of 1.56, 3.125, 6.25, 12.5, 25,
50, 100, 200, and 250 μM, as well as DA and AQ in
quantities of 0.007, 0.015, 0.03, 0.06, 0.125, 0.25, 0.5, and
1 μM, were placed in a 96-well plate in triplicate to de-
termine inhibition concentrations, with a 2.5%
hematocrit for B. bovis and B. bigemina and a 5%
hematocrit for B. divergens, B. caballi, and T. equi. Wells
containing infected red blood cells (iRBCs) were used as
positive controls, while wells with non-infected red
blood cells (RBCs) were used as negative controls. The
plate was incubated at 37 °C in a humidified multi-gas
water-jacketed incubator with an atmosphere of 5%
CO2, 5% O2, and 90% N2 for 96 h without changing
media. After 96 h, 100 μL of lysis buffer containing SGI
was directly added to each well and mixed gently by pip-
etting, wrapped in aluminum foil for protection from
direct light, and incubated for 6 h at room temperature.
The plate was then placed into the fluorescence spectro-
photometer (Fluoroskan Ascent, Thermo LabSystems,
Oceanside, California, USA). Relative fluorescence values
were read at 485 and 518 nm for excitation and emission
wavelengths, respectively. Gain values were set to per-
centages after subtraction of the mean values of the
negative control and transferred into GraphPad Prism
(GraphPad Software Inc. San Diego, CA, USA) to calcu-
late the IC50 value using the nonlinear regression ana-
lysis (curve fit).
Viability experiment in vitro
The assay was conducted in accordance with the proto-
col described previously [28]. Briefly, a 100 μL reaction
volume, containing 90 μL of medium with different drug
concentrations (0.25×, 0.5×, 1×, 2×, and 4× the IC50 of
IVM and DA) and 10 μL of iRBCs adjusted to 1% para-
sitemia, was incubated in a 96-well microtiter plate at
37 °C in a humidified multi-gas water-jacketed incuba-
tor. The medium was changed daily for 4 days and re-
placed with new medium containing the same
concentrations of drugs. In the course of treatment,
Giemsa-stained thin blood smears were prepared, and
the parasitemia was monitored every 12 h by counting
the number of infected RBCs among 2000 RBCs. On day
Batiha et al. Tropical Medicine and Health           (2019) 47:42 Page 9 of 12
5, 3 μL of treated RBCs from each well was mixed with
7 μL of fresh RBCs, transferred into a new 96-well mi-
crotiter plate, and cultured in drug-free medium. The
medium was replaced every day, and the viability of
drug-treated parasites was checked in Giemsa-stained
thin blood smears 6 days after the last treatment. Parasit-
emia was calculated. The presence of parasites was re-
corded as positive (relapse), while no parasite was recorded
as negative (total parasite clearance). Each experiment was
performed in triplicate in three separate trials.
Combination treatment of IVM with DA, AQ, and CF in
vitro
The combination assay was conducted in accordance
with the protocol previously described [32] in three sep-
arate trials. Three sets of duplicate wells with five se-
lected concentrations, 0.25×, 0.5×, 1×, 2×, and 4× the
IC50 of IVM with DA, AQ, and CF were cultivated in a
96-well plate (Additional file 1: Table S1). IVM single
treatments were added to the first set of wells, while the
second set of wells contained various concentrations of
DA, AQ, or CF single treatments, and the third set con-
tained the combinations of IVM with DA, AQ, or CF
(IVM + DA, IVM + AQ, IVM + CF) at a constant ratio
(1:1) [18]. One hundred microliter reaction volumes of
media containing the drug concentrations and 2.5% and
5% hematocrits for B. bovis and B. bigemina and B.
divergens, B. caballi, and T. equi, respectively, were culti-
vated for 4 days in a humidified incubator with 5% CO2,
5% O2, and 90% N2. On day 4, 100 μL of lysis buffer
containing 2 × SG1 was added, and the plate was
wrapped with aluminum foil for protection from light
and incubated for 6 h at room temperature. Afterward,
the plate was loaded into a fluorescence spectrophotom-
eter, and the relative fluorescence values were read at
485 and 518 nm for excitation and emission wave-
lengths, respectively. The obtained fluorescence values
were set to percentages after subtracting the mean
values of the negative control. The growth inhibition
values obtained were entered into Compusyn software
for calculating the degree of association based on the
combination index (CI) values. The CI values of the drug
combination were determined using the formula [(1 ×
IC50) + (2 × IC75) + (3 × IC90) + (4 × IC95)]/10 (Additional
file 2: Table S2), and the results were described as syner-
gistic, additive, or antagonistic in accordance with the
combination index scale: < 0.90, 0.90–1.10, and > 1.10,
respectively [18].
Chemotherapeutic effects of IVM against B. microti
The in vivo inhibitory effects of IVM were evaluated
against B. microti in mice as previously described [28].
Briefly, B. microti recovered from frozen stock (stored at
− 80 °C) was thawed and injected into two mice
intraperitoneally. The parasitemia was monitored every
day by microscopy, and when the parasitemia was over
30%, the mice were sacrificed, and blood was collected
by cardiac puncture. After that, phosphate-buffered sa-
line was used to dilute the blood to obtain an inoculum
containing 1 × 107/mL of B. microti iRBCs. Forty-five fe-
male 8-week-old BALB/c mice were caged in nine
groups. The mice in group 1 were left uninfected to act
as the negative control, while groups 2–9 were injected
intraperitoneally (i.p.) with 0.5 mL of inoculum (1 × 107
B. microti iRBCs). When the average parasitemia in all
mice reached 1%, drug treatment was initiated for 5 days.
The mice in group 2 were administered 0.2 mL of DDW
intraperitoneally to act as the positive control, while
groups 3 and 4 were i.p. injected with 0.2 mL of 25 mg/
kg DA and 4 mg/kg of IVM single treatment, respect-
ively. Groups 5 and 6 received 0.2 mL 20 mg/kg AQ and
20 mg/kg CF single treatment orally, respectively.
Groups 7–9 were treated with combinations of IVM
+ DA, IVM + AQ, and IVM + CF, respectively. The
parasitemia and hematocrit were monitored every 2
and 4 days for 45 days by microscopy and a
hematology analyzer (Celltac α MEK-6450, Nihon
Kohden Corporation, Tokyo, Japan), respectively. On
day 49, all mice were anesthetized, and the blood was
collected by cardiac puncture for PCR detection of
parasites. The experiment was conducted two times.
The significant differences between groups were de-
termined by independent Student’s t test and one-way
ANOVA Tukey’s test using GraphPad Prism version
5.0 for Windows (GraphPad Software Inc., San Diego,
CA, USA). A p value of < 0.05 was considered statis-
tically significant.
Genomic DNA extraction and PCR detection of B. microti
A nested PCR (nPCR) targeting the B. microti small-
subunit rRNA (ss-rRNA) gene was carried out in accord-
ance with the previously described protocol [28, 35] after
extracting the genomic DNA from the blood using a
QIAamp DNA Blood Mini Kit (Qiagen, Tokyo, Japan).
Briefly, a 10 μL reaction mixture containing 0.5 μM of
each primer, 2 μL of 5 × SuperFi™ buffer, 0.2 mM dNTP
mix, 0.1 μL of Platinum SuperFi™ DNA polymerase
(Thermo Fisher Scientific, Tokyo, Japan), 1 μL of DNA
template, and 4.9 μL of DDW was used to conduct the
PCR amplification. The cycling conditions were 94 °C,
53 °C, and 72 °C for 30 s as denaturation, annealing, and
extension steps for 35 cycles using the forward (5′-CTTA
GTATAAGCTTTTATACAGC-3′) and reverse primer
(5′-ATAGGTCAGAAACTTGAATGATACA-3′). Subse-
quently, under similar cycling conditions, 1 μL of DNA
template from the first PCR amplification was used as the
template for the nPCR assay using the forward (5′-GTTA-
TAGTTTATTTGATGTTCGTTT-3′) and reverse primers
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(5′-AAGCCATGCGATTCGCTAAT-3′). The PCR prod-
ucts were then resolved by electrophoresis in a 1.5% agar-
ose gel, stained with ethidium bromide, and visualized
under the UV transilluminator. The bands with an ex-
pected size of 154 bp were considered positive.
Statistical analysis
The IC50 values of IVM, DA, AQ, and CF were deter-
mined using the nonlinear regression curve fit in Graph-
Pad Prism (GraphPad Software Inc., San Diego, CA,
USA). Differences in parasitemia, hematology profiles,
and body weight were analyzed using an independent
Student’s t test and one-way ANOVA Tukey’s test using
GraphPad Prism version 5.0 for Windows (GraphPad
Software Inc., San Diego, CA, USA). A p value < 0.05
was considered statistically significant.
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